Apremilast Clinical Trials (2026): 137 Studies for Psoriasis & Psoriatic Arthritis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
137 Apremilast clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 62 indications (including Psoriasis & Psoriatic Arthritis) and 45,935 total planned enrollment. 37 Phase 3 Apremilast trials and 40 Phase 2, 29 Phase 4 are listed. 17 Apremilast clinical trials are actively recruiting at 13 U.S. sites across 13 states. Most recent activity: NCT05767047 (Mar 2036).
Where to Participate: All Apremilast Trial Sites in the U.S. (13 sites across 13 states)
Every actively recruiting Apremilasttrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | University of California | Los Angeles90095 | NCT07325266 | Map |
| CO | University of Colorado | Aurora80045 | NCT07325266 | Map |
| CT | Yale University | New Haven06510 | NCT07029529 | Map |
| FL | University of Florida | Jacksonville32209 | NCT02735707 | Map |
| IL | University of Illinois Health | Chicago60612 | NCT02735707 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT05703685 | Map |
| MA | Local Institution | Waltham02451 | NCT05744466 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT02735707 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT02735707 | Map |
| OH | The Ohio State University Wexner Medical Center | Columbus43210 | NCT02735707 | Map |
| OR | Oregon Health and Science University | Portland97239-3098 | NCT02735707 | Map |
| PA | University of Pittsburgh Medical Centre | Pittsburgh | NCT02735707 | Map |
| VA | University of Virginia | Charlottesville22911 | NCT07325266 | Map |
Apremilast clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | terminated | withdrawn | not yet recruiting | unknown | Total |
|---|---|---|---|---|---|---|---|---|---|
| Early P1 | 1 | 1 | |||||||
| P1 | 1 | 1 | 8 | 10 | |||||
| P1/P2 | 1 | 1 | 2 | ||||||
| P2 | 3 | 1 | 28 | 2 | 4 | 2 | 40 | ||
| P3 | 5 | 3 | 27 | 2 | 37 | ||||
| P4 | 1 | 16 | 4 | 2 | 6 | 29 | |||
| N/A | 2 | 1 | 12 | 1 | 2 | 18 |
Recruiting Apremilast clinical trials (17)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05767047 | A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis | P3 | Behçet's Disease | 48 | Mar 2023 |
| NCT04528082 | BEANApremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease | P3 | Behçet Disease | 60 | Sep 2021 |
| NCT07029529 | Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder | P2 | Alcohol Use Disorder | 80 | May 2026 |
| NCT07352566 | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis | P4 | Psoriasis | 10 | Aug 2026 |
| NCT06382987 | RePhlectA Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect) | — | Plaque Psoriasis | 600 | Jan 2024 |
| NCT05703685 | [18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET | P1 | Depression | 108 | Jun 2023 |
| NCT04804553 | PEAPODApremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis | P3 | Active Juvenile Psoriatic Arthritis | 60 | Mar 2022 |
| NCT07366268 | Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis | N/A | Psoriasis | 36 | May 2026 |
| NCT02735707 | REMAP-CAPRandomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | P3 | Community-acquired Pneumonia, Influenza, COVID-19 | 20,000 | Apr 2016 |
| NCT05744466 | RePhlectA Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis | — | Psoriasis | 1,500 | Sep 2022 |
| NCT07325266 | Human Laboratory Study of Apremilast for Alcohol Use Disorder | P2 | Alcohol Use Disorder | 100 | Apr 2026 |
| NCT06593197 | Efficacy and Safety of Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients | P4 | Vitiligo | 30 | Jan 2025 |
| NCT04227314 | PREMSRandomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis | P3 | Recurrent Aphtous Stomatitis | 134 | Apr 2022 |
| NCT07398651 | Apremilast and Adalimumab in Psoriatic Arthritis Patients | N/A | Psoriatic Arthritis | 60 | Dec 2026 |
| NCT07432386 | Methotrexate Versus Apremilast for Pruritus in Psoriasis | P4 | Psoriasis | 80 | May 2026 |
| NCT07337434 | To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital | Early P1 | Chronic Plaque Psoriasis | 106 | Dec 2025 |
| NCT06509984 | EBULOA 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized | P2 | Epidermolysis Bullosa Simplex | 20 | Aug 2024 |
Apremilast clinical trials by indication
Psoriasis (29)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07352566 | — | P4 | not yet recruiting | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis |
| NCT07366268 | — | N/A | not yet recruiting | Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis |
| NCT05744466 | RePhlect | N/A | recruiting | A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis |
| NCT07432386 | — | P4 | not yet recruiting | Methotrexate Versus Apremilast for Pruritus in Psoriasis |
| NCT04175613 | CC-10004 | P3 | completed | A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis |
| NCT05863273 | — | N/A | completed | Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT） |
| NCT07169682 | — | N/A | completed | Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis |
| NCT02144857 | — | P4 | unknown | Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis |
| + 21 more, see All trials below. | ||||
Plaque Psoriasis (16)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06382987 | RePhlect | N/A | recruiting | A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect) |
| NCT05565560 | — | P3 | active not recruiting | A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis |
| NCT06088199 | — | P3 | active not recruiting | A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis |
| NCT06588738 | ONWARD2 | P3 | completed | A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 |
| NCT06122649 | ESSENCE | P3 | completed | A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) |
| NCT06586112 | ONWARD1 | P3 | completed | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis |
| NCT06108544 | — | P3 | completed | A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period |
| NCT06088043 | — | P3 | completed | A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
| + 8 more, see All trials below. | ||||
Psoriatic Arthritis (13)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07398651 | — | N/A | not yet recruiting | Apremilast and Adalimumab in Psoriatic Arthritis Patients |
| NCT04908189 | — | P3 | active not recruiting | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment |
| NCT04610476 | — | P3 | unknown | Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis |
| NCT02775500 | — | N/A | active not recruiting | Apremilast Pregnancy Exposure Registry |
| NCT03783026 | MOSAIC | P4 | completed | A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis |
| NCT04102449 | PSA-ULTRA | P4 | withdrawn | Validation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With Apremilast |
| NCT01307423 | PALACE4 | P3 | completed | Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA) |
| NCT01212770 | PALACE 3 | P3 | completed | PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis |
| + 5 more, see All trials below. | ||||
Alcohol Use Disorder (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07029529 | — | P2 | recruiting | Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder |
| NCT07325266 | — | P2 | recruiting | Human Laboratory Study of Apremilast for Alcohol Use Disorder |
| NCT06324435 | — | P1 | active not recruiting | Apremilast for Alcohol Use Disorder Treatment in Women and Men |
| NCT03175549 | — | P2 | completed | Medication Development in Alcoholism: Apremilast Versus Placebo |
Arthritis, Psoriatic (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03747939 | FOREMOST | P4 | completed | Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. |
| NCT03608657 | APPRAISE | N/A | completed | Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE) |
| NCT03828045 | PREVAIL | N/A | completed | A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment |
| NCT03096990 | APOLO | N/A | completed | A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium |
Vitiligo (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06593197 | — | P4 | enrolling by invitation | Efficacy and Safety of Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients |
| NCT03036995 | Rapid Vitiligo | P2 | completed | Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO |
| NCT03123016 | — | P2 | completed | Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo |
Atopic Dermatitis (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04306965 | BID | P2 | completed | Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab |
| NCT01393158 | — | P2 | completed | Apremilast for Atopic Dermatitis - A Pilot Study in Adults |
| NCT00931242 | — | P2 | completed | Study of Apremilast in Atopic or Contact Dermatitis |
Healthy Volunteers (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02777554 | — | P1 | completed | A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults |
| NCT02641353 | PK | P1 | completed | Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension |
| NCT02236988 | — | P1 | completed | Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men |
Chronic Plaque Psoriasis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07337434 | — | Early P1 | recruiting | To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital |
| NCT01200264 | CPP | P2 | withdrawn | Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy |
Oral Lichen Planus (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06260904 | — | P4 | completed | Efficacy and Safety of add-on Apremilast Versus add-on Methotrexate in Patients With Oral Lichen Planus |
| NCT03836885 | APOLP | P2 | withdrawn | Apremilast - Oral Lichen Planus Trial |
Alopecia Areata (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05926882 | — | P4 | completed | Efficacy of Oral Apremilast in the Treatment of Alopecia Areata at the Tertiary Care Hospital, Karachi. |
| NCT02684123 | — | N/A | completed | Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata |
Palmoplantar Pustulosis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05174065 | PPP | P3 | completed | Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP) |
| NCT04572997 | APLANTUS | P2 | completed | Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS) |
COVID-19 (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04488081 | I-SPY_COVID | P2 | active not recruiting | I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients |
| NCT04590586 | COMMUNITY | P3 | completed | Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients |
Hidradenitis Suppurativa (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03049267 | SMASH | P2 | completed | Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis |
| NCT02695212 | HS | P2 | completed | Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa |
Healthy Volunteer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01634191 | — | P1 | completed | Effects of Age and Sex on the Pharmacokinetics of Apremilast in Healthy Adults |
| NCT01634178 | CC-10004 | P1 | completed | Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Adults |
Rheumatoid Arthritis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01250548 | CARAT | P2 | completed | The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT) |
| NCT01285310 | — | P2 | terminated | Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis |
Epidermolysis Bullosa Simplex (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06509984 | EBULO | P2 | recruiting | A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized |
Depression (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05703685 | — | P1 | recruiting | [18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET |
Behçet's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05767047 | — | P3 | recruiting | A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis |
Psoriasis and Psoriatic Arthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06084663 | — | P3 | completed | Bioequivalence Study of Two Products of Apremilast 30 mg Tablets in Healthy, Adult, Human Subjects |
Recurrent Aphtous Stomatitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04227314 | PREMS | P3 | recruiting | Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis |
Active Juvenile Psoriatic Arthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04804553 | PEAPOD | P3 | recruiting | Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis |
Erythema Multiforme (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05875714 | AEM | P2 | completed | Apremilast for Erythema Multiforme |
Behçet Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04528082 | BEAN | P3 | recruiting | Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease |
Palmoplantaris Pustulosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04057937 | CC-10004 | P2 | completed | A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis |
Acne Conglobata (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04161456 | APACCO | P2 | completed | Preliminary Efficacy and Safety of Apremilast in the Treatment of Acne Conglobata |
Lichen Planus of Vulva (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03656666 | — | P2 | unknown | The AP-GELP Study: A Clinical Trial on the Effects of Apremilast in Female Genital Erosive Lichen Planus |
Erythema Nodosum Leprosum (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04822909 | — | P4 | completed | A Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum Leprosum |
Chronic Hand Dermatitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03741933 | CHD | P4 | withdrawn | Apremilast and Moderate to Severe Chronic Hand Dermatitis |
Central Centrifugal Cicatricial Alopecia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03521687 | CCCA | P4 | completed | Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) |
Recurrent Aphthous Stomatitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03690544 | — | P4 | completed | Apremilast for RAS |
Frontal Fibrosing Alopecia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03422640 | — | P4 | unknown | Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia |
Psoriasis of Scalp (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03553433 | APRESCALP | P4 | unknown | Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis |
Dermatomyositis, Adult Type (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03529955 | — | P2 | completed | Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis |
Nail Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03616561 | JUST | N/A | completed | Quality of Life and Ultrasonographic Assessment of Nail Psoriasis After Treatment With Apremilast (JUST Study) |
Itch (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03239106 | — | P2 | completed | A Study Examining the Medication Apremilast as Treatment for Chronic Itch |
Arthritis; Psoriasis (Etiology) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03191539 | APREMILAST | P3 | unknown | Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis |
Moderate to Severe Plaque Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03146247 | Itch | P4 | withdrawn | Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients |
Nummular Eczema (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03160248 | APREMINUM | P2 | completed | An Investigator-initiated Study of Apremilast to Demonstrate Efficacy Nummular Eczema |
Prurigo Nodularis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03576287 | — | P1/P2 | unknown | Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis |
Psoriatic Nail (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03022617 | — | P4 | completed | A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis |
Healthy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02963779 | — | P1 | completed | A Study of LY2775240 in Healthy Participants |
Pharmacokinetics (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02802735 | — | P1 | completed | Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean Subjects |
Community-acquired Pneumonia, Influenza, COVID-19 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02735707 | REMAP-CAP | P3 | recruiting | Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia |
Palmo-plantar Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02400749 | — | P4 | completed | Apremilast in Palmo-Plantar Psoriasis |
Parapsoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02425826 | UNVEIL | P4 | completed | A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis. |
Ulcerative Colitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02289417 | UC | P2 | completed | Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis |
Behçet's Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02307513 | CC-10004 | P3 | completed | A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease |
Dermatitis, Atopic Dermatitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02087943 | — | P2 | completed | Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis |
Ankylosing Spondyloarthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01583374 | POSTURE | P3 | completed | Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis |
Healthy Subjects (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01561963 | — | P1 | completed | A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast |
Arthritis, Rheumatoid (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01204138 | CATARA | P2 | withdrawn | Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA |
Erosive Osteoarthritis of the Hand (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01200472 | CC-10004 | P2 | completed | Efficacy Study of Apremilast (CC-10004) in Subjects With Erosive Hand Osteoarthritis |
Erythematotelangiectatic Rosacea (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01045551 | — | P2 | completed | Open Label Pilot Study of Apremilast in Treatment of Rosacea |
Acute Gout (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00997581 | — | P2 | withdrawn | Apremilast Therapy for Acute Gouty Arthritis |
Dermatomyositis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01140503 | — | N/A | terminated | A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis |
Acne (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01074502 | — | P2 | terminated | Apremilast in the Treatment of Moderate to Severe Acne |
Lichen Planus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01041625 | CC-10004 | P2 | unknown | Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus |
Uveitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00889421 | — | P1/P2 | terminated | Apremilast in the Treatment of Uveitis |
Ankylosing Spondylitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00944658 | START | P2 | completed | Spondylitis Trial of Apremilast for Better Rheumatic Therapy |
Behcet Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00866359 | CC-10004 | P2 | completed | A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease |
Psoriasis-Type Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00521339 | — | P2 | completed | Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis |
Apremilast pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| FOREMOST | NCT03747939 | P4 | completed | Arthritis, Psoriatic | 310 | PMID 42384964 |
| MOSAIC | NCT03783026 | P4 | completed | Psoriatic Arthritis | 123 | PMID 39488216 |
| PSA-ULTRA | NCT04102449 | P4 | withdrawn | Psoriatic Arthritis | 0 | — |
| EMBRACE | NCT03774875 | P4 | completed | Psoriasis | 277 | PMID 36300769 |
| DANPAPP | NCT04515732 | P4 | unknown | Psoriasis | 115 | — |
| VIP-A | NCT03082729 | P4 | completed | Psoriasis | 70 | PMID 36129688 |
| CCCA | NCT03521687 | P4 | completed | Central Centrifugal Cicatricial Alopecia | 20 | — |
| APRESCALP | NCT03553433 | P4 | unknown | Psoriasis of Scalp | 90 | — |
| CHD | NCT03741933 | P4 | withdrawn | Chronic Hand Dermatitis | 0 | PMID 21658053 |
| Itch | NCT03146247 | P4 | withdrawn | Moderate to Severe Plaque Psoriasis | 0 | — |
| UNVEIL | NCT02425826 | P4 | completed | Parapsoriasis | 221 | PMID 29462231 |
| BEAN | NCT04528082 | P3 | recruiting | Behçet Disease | 60 | — |
| PEAPOD | NCT04804553 | P3 | recruiting | Active Juvenile Psoriatic Arthritis | 60 | — |
| REMAP-CAP | NCT02735707 | P3 | recruiting | Community-acquired Pneumonia, Influenza, COVID-19 | 20,000 | PMID 37039790 |
| PREMS | NCT04227314 | P3 | recruiting | Recurrent Aphtous Stomatitis | 134 | — |
| ONWARD2 | NCT06588738 | P3 | completed | Plaque Psoriasis | 862 | — |
| CC-10004 | NCT04175613 | P3 | completed | Psoriasis | 160 | — |
| ESSENCE | NCT06122649 | P3 | completed | Plaque Psoriasis | 203 | — |
| ONWARD1 | NCT06586112 | P3 | completed | Plaque Psoriasis | 912 | — |
| PPP | NCT05174065 | P3 | completed | Palmoplantar Pustulosis | 176 | PMID 41297955 |
| CC-10004 | NCT03701763 | P3 | completed | Psoriasis | 245 | PMID 38266683 |
| DISCREET | NCT03777436 | P3 | completed | Psoriasis | 289 | PMID 41369155 |
| COMMUNITY | NCT04590586 | P3 | completed | COVID-19 | 515 | — |
| POETYK-PSO-2 | NCT03611751 | P3 | completed | Psoriasis | 1,020 | PMID 37150956 |
| POETYK-PSO-1 | NCT03624127 | P3 | completed | Psoriasis | 666 | PMID 40066907 |
| ADVANCE | NCT03721172 | P3 | completed | Psoriasis | 595 | PMID 34343599 |
| CC-10004 | NCT02307513 | P3 | completed | Behçet's Syndrome | 207 | PMID 35798511 |
| APREMILAST | NCT03191539 | P3 | unknown | Arthritis; Psoriasis (Etiology) | 56 | — |
| STYLE | NCT03123471 | P3 | completed | Psoriasis | 303 | PMID 30747550 |
| POSTURE | NCT01583374 | P3 | completed | Ankylosing Spondyloarthritis | 490 | PMID 33589554 |
| PALACE4 | NCT01307423 | P3 | completed | Psoriatic Arthritis | 529 | PMID 29635379 |
| PALACE 3 | NCT01212770 | P3 | completed | Psoriatic Arthritis | 505 | PMID 26792812 |
| PALACE2 | NCT01212757 | P3 | completed | Psoriatic Arthritis | 488 | PMID 30018799 |
| ESTEEM 2 | NCT01232283 | P3 | completed | Plaque Psoriasis | 413 | — |
| ESTEEM 1 | NCT01194219 | P3 | completed | Plaque Psoriasis | 844 | PMID 34255891 |
| PALACE-1 | NCT01172938 | P3 | completed | Psoriatic Arthritis | 504 | PMID 25593233 |
| I-SPY_COVID | NCT04488081 | P2 | active not recruiting | COVID-19 | 1,500 | PMID 39592213 |
| EBULO | NCT06509984 | P2 | recruiting | Epidermolysis Bullosa Simplex | 20 | PMID 41224305 |
| AEM | NCT05875714 | P2 | completed | Erythema Multiforme | 6 | — |
| BID | NCT04306965 | P2 | completed | Atopic Dermatitis | 10 | — |
| APREMINUM | NCT03160248 | P2 | completed | Nummular Eczema | 31 | — |
| CC-10004 | NCT04057937 | P2 | completed | Palmoplantaris Pustulosis | 90 | PMID 37233897 |
| APACCO | NCT04161456 | P2 | completed | Acne Conglobata | 1 | — |
| APOLP | NCT03836885 | P2 | withdrawn | Oral Lichen Planus | 0 | — |
| Rapid Vitiligo | NCT03036995 | P2 | completed | Vitiligo | 80 | PMID 32004567 |
| APLANTUS | NCT04572997 | P2 | completed | Palmoplantar Pustulosis | 21 | PMID 34077577 |
| CC-10004 | NCT02576678 | P2 | completed | Psoriasis | 42 | PMID 31408686 |
| UC | NCT02289417 | P2 | completed | Ulcerative Colitis | 170 | PMID 31926340 |
| SMASH | NCT03049267 | P2 | completed | Hidradenitis Suppurativa | 20 | — |
| HS | NCT02695212 | P2 | completed | Hidradenitis Suppurativa | 20 | — |
| CC-10004 | NCT01988103 | P2 | completed | Psoriasis | 254 | PMID 28391657 |
| CC-10004 | NCT00773734 | P2 | completed | Psoriasis | 352 | PMID 23663752 |
| CARAT | NCT01250548 | P2 | completed | Rheumatoid Arthritis | 34 | — |
| CC-10004 | NCT01200472 | P2 | completed | Erosive Osteoarthritis of the Hand | 30 | — |
| CPP | NCT01200264 | P2 | withdrawn | Chronic Plaque Psoriasis | 0 | — |
| CC-10004 | NCT00866359 | P2 | completed | Behcet Syndrome | 111 | PMID 25875256 |
| CC-10004 | NCT01041625 | P2 | unknown | Lichen Planus | 10 | PMID 22910104 |
| CATARA | NCT01204138 | P2 | withdrawn | Arthritis, Rheumatoid | 0 | — |
| START | NCT00944658 | P2 | completed | Ankylosing Spondylitis | 38 | PMID 22984171 |
| CC-10004 | NCT00456092 | P2 | completed | Psoriatic Arthritis | 204 | PMID 23588944 |
Terminated and withdrawn Apremilast trials (12)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT04102449withdrawnValidation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With Apremilast
- NCT03836885withdrawnApremilast - Oral Lichen Planus Trial
- NCT03741933withdrawnApremilast and Moderate to Severe Chronic Hand Dermatitis
- NCT03146247withdrawnAnalysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients
- NCT02558361withdrawnTreatment With Apremilast in Patients With Psoriatic Arthritis
- NCT01200264withdrawnApremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy
- NCT01285310terminatedStudy of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
- NCT01204138withdrawnConcomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
- NCT01140503terminatedA Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis
- NCT00889421terminatedApremilast in the Treatment of Uveitis
- NCT00997581withdrawnApremilast Therapy for Acute Gouty Arthritis
- NCT01074502terminatedApremilast in the Treatment of Moderate to Severe Acne
All Apremilast trials (137)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05767047 | A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis | P3 | recruiting | 48 | Amgen | Mar 2023 | |
| NCT04528082 | BEAN | Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease | P3 | recruiting | 60 | Amgen | Sep 2021 |
| NCT07029529 | Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder | P2 | recruiting | 80 | Yale University | May 2026 | |
| NCT04488081 | I-SPY_COVID | I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients | P2 | active not recruiting | 1,500 | QuantumLeap Healthcare Collaborative | Jul 2020 |
| NCT07352566 | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis | P4 | not yet recruiting | 10 | University of California, San Francisco | Aug 2026 | |
| NCT06382987 | RePhlect | A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect) | — | recruiting | 600 | Bristol-Myers Squibb | Jan 2024 |
| NCT05703685 | [18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET | P1 | recruiting | 108 | National Institute of Mental Health (NIMH) | Jun 2023 | |
| NCT04804553 | PEAPOD | Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis | P3 | recruiting | 60 | Amgen | Mar 2022 |
| NCT07366268 | Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis | N/A | not yet recruiting | 36 | Assiut University | May 2026 | |
| NCT02735707 | REMAP-CAP | Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | P3 | recruiting | 20,000 | UMC Utrecht | Apr 2016 |
| NCT05744466 | RePhlect | A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis | — | recruiting | 1,500 | Bristol-Myers Squibb | Sep 2022 |
| NCT07325266 | Human Laboratory Study of Apremilast for Alcohol Use Disorder | P2 | recruiting | 100 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Apr 2026 | |
| NCT06593197 | Efficacy and Safety of Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients | P4 | enrolling by invitation | 30 | Dow University of Health Sciences | Jan 2025 | |
| NCT04227314 | PREMS | Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis | P3 | recruiting | 134 | University Hospital, Rouen | Apr 2022 |
| NCT07398651 | Apremilast and Adalimumab in Psoriatic Arthritis Patients | N/A | not yet recruiting | 60 | Tanta University | Dec 2026 | |
| NCT04908189 | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment | P3 | active not recruiting | 729 | Bristol-Myers Squibb | Jul 2021 | |
| NCT07432386 | Methotrexate Versus Apremilast for Pruritus in Psoriasis | P4 | not yet recruiting | 80 | Zarmeen Khawar | May 2026 | |
| NCT05565560 | A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis | P3 | active not recruiting | 17 | Amgen | Jan 2023 | |
| NCT06324435 | Apremilast for Alcohol Use Disorder Treatment in Women and Men | P1 | active not recruiting | 10 | Yale University | May 2024 | |
| NCT06088199 | A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis | P3 | active not recruiting | 51 | Amgen | Oct 2023 | |
| NCT07337434 | To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital | Early P1 | recruiting | 106 | Syeda Sana Zaman | Dec 2025 | |
| NCT06509984 | EBULO | A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized | P2 | recruiting | 20 | Centre Hospitalier Universitaire de Nice | Aug 2024 |
| NCT06588738 | ONWARD2 | A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 | P3 | completed | 862 | Alumis Inc | Aug 2024 |
| NCT04175613 | CC-10004 | A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis | P3 | completed | 160 | Amgen | Dec 2019 |
| NCT06122649 | ESSENCE | A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) | P3 | completed | 203 | Amgen | Nov 2023 |
| NCT06586112 | ONWARD1 | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis | P3 | completed | 912 | Alumis Inc | Jul 2024 |
| NCT06108544 | A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period | P3 | completed | 1,108 | Takeda | Nov 2023 | |
| NCT06260904 | Efficacy and Safety of add-on Apremilast Versus add-on Methotrexate in Patients With Oral Lichen Planus | P4 | completed | 64 | All India Institute of Medical Sciences, Bhubaneswar | Jan 2024 | |
| NCT06088043 | A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment | P3 | completed | 693 | Takeda | Nov 2023 | |
| NCT04610476 | Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis | P3 | unknown | 270 | University of Erlangen-Nürnberg Medical School | Oct 2020 | |
| NCT02775500 | Apremilast Pregnancy Exposure Registry | — | active not recruiting | 233 | University of California, San Diego | Nov 2014 | |
| NCT05863273 | Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT） | — | completed | 360 | First Hospital of China Medical University | May 2023 | |
| NCT05875714 | AEM | Apremilast for Erythema Multiforme | P2 | completed | 6 | Robert Micheletti | Jan 2022 |
| NCT07169682 | Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis | — | completed | 66 | National and Kapodistrian University of Athens | Sep 2021 | |
| NCT05174065 | PPP | Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP) | P3 | completed | 176 | Amgen | Mar 2022 |
| NCT03656666 | The AP-GELP Study: A Clinical Trial on the Effects of Apremilast in Female Genital Erosive Lichen Planus | P2 | unknown | 42 | Oslo University Hospital | Sep 2019 | |
| NCT02144857 | Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis | P4 | unknown | 200 | University of Athens | May 2014 | |
| NCT06032858 | Efficacy and Safety of Apremilast in Psoriasis | P4 | completed | 30 | Ghurki Trust and Teaching Hospital | Mar 2022 | |
| NCT03747939 | FOREMOST | Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. | P4 | completed | 310 | Amgen | Dec 2018 |
| NCT05926882 | Efficacy of Oral Apremilast in the Treatment of Alopecia Areata at the Tertiary Care Hospital, Karachi. | P4 | completed | 30 | Jinnah Postgraduate Medical Centre | Aug 2022 | |
| NCT06084663 | Bioequivalence Study of Two Products of Apremilast 30 mg Tablets in Healthy, Adult, Human Subjects | P3 | completed | 36 | Humanis Saglık Anonim Sirketi | Feb 2023 | |
| NCT04908475 | Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy | P4 | completed | 352 | AbbVie | Jun 2021 | |
| NCT03701763 | CC-10004 | Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis | P3 | completed | 245 | Amgen | Dec 2018 |
| NCT03022617 | A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis | P4 | completed | 12 | University of Alabama at Birmingham | Jan 2017 | |
| NCT04306965 | BID | Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab | P2 | completed | 10 | Tufts Medical Center | Aug 2020 |
| NCT02954081 | APART | APremilast After FumaRic Acid Ester Treatment | — | completed | 687 | Amgen | Jan 2017 |
| NCT03783026 | MOSAIC | A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis | P4 | completed | 123 | Amgen | Feb 2019 |
| NCT03168256 | CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis | P3 | completed | 528 | Can-Fite BioPharma | Sep 2018 | |
| NCT03608657 | APPRAISE | Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE) | — | completed | 102 | Amgen | Jul 2018 |
| NCT04102449 | PSA-ULTRA | Validation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With Apremilast | P4 | withdrawn | 0 | Medical University of Graz | Jul 2020 |
| NCT03777436 | DISCREET | An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis | P3 | completed | 289 | Amgen | Feb 2019 |
| NCT03774875 | EMBRACE | A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life | P4 | completed | 277 | Amgen | Mar 2019 |
| NCT04515732 | DANPAPP | Danish Population-based Assessment of Psoriasis and Psoriatic Arthritis (DANPAPP) | P4 | unknown | 115 | Professor Mikkel Østergaard | Dec 2018 |
| NCT03828045 | PREVAIL | A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment | — | completed | 119 | Amgen | Feb 2019 |
| NCT04555707 | The Maintenance Effect of Enstilar Foam in Combination With Otezla | P4 | unknown | 30 | Derm Research, PLLC | Jun 2020 | |
| NCT03442088 | Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast | P2 | completed | 28 | University Hospitals Cleveland Medical Center | Jun 2018 | |
| NCT03160248 | APREMINUM | An Investigator-initiated Study of Apremilast to Demonstrate Efficacy Nummular Eczema | P2 | completed | 31 | Technical University of Munich | Jul 2017 |
| NCT03757013 | REALIZE | A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France | — | completed | 453 | Amgen | Sep 2018 |
| NCT03082729 | VIP-A | Vascular Inflammation in Psoriasis - Apremilast | P4 | completed | 70 | University of Pennsylvania | Apr 2017 |
| NCT04590586 | COMMUNITY | Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients | P3 | completed | 515 | Amgen | Nov 2020 |
| NCT03690544 | Apremilast for RAS | P4 | completed | 15 | Mayo Clinic | Oct 2018 | |
| NCT04057937 | CC-10004 | A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis | P2 | completed | 90 | Amgen | Oct 2019 |
| NCT03529955 | Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis | P2 | completed | 8 | Tulane University | Jun 2018 | |
| NCT03521687 | CCCA | Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) | P4 | completed | 20 | Icahn School of Medicine at Mount Sinai | Nov 2018 |
| NCT04161456 | APACCO | Preliminary Efficacy and Safety of Apremilast in the Treatment of Acne Conglobata | P2 | completed | 1 | Dr. Frank Behrens | Oct 2019 |
| NCT04031027 | DARWIN | A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical Practice | — | completed | 184 | Amgen | Jul 2019 |
| NCT03611751 | POETYK-PSO-2 | An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis | P3 | completed | 1,020 | Bristol-Myers Squibb | Jul 2018 |
| NCT03930186 | A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy | P3 | completed | 152 | Amgen | Jun 2019 | |
| NCT03624127 | POETYK-PSO-1 | Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis | P3 | completed | 666 | Bristol-Myers Squibb | Aug 2018 |
| NCT03721172 | ADVANCE | Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy | P3 | completed | 595 | Amgen | Mar 2019 |
| NCT03616561 | JUST | Quality of Life and Ultrasonographic Assessment of Nail Psoriasis After Treatment With Apremilast (JUST Study) | — | completed | 45 | Hospital de Granollers | Feb 2018 |
| NCT02307513 | CC-10004 | A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease | P3 | completed | 207 | Amgen | Dec 2014 |
| NCT04822909 | A Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum Leprosum | P4 | completed | 10 | Post Graduate Institute of Medical Education and Research, Chandigarh | Sep 2019 | |
| NCT03553433 | APRESCALP | Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis | P4 | unknown | 90 | University of Zurich | Jun 2018 |
| NCT03453190 | Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis | P4 | unknown | 20 | Washington Dermatology Center | Feb 2018 | |
| NCT03836885 | APOLP | Apremilast - Oral Lichen Planus Trial | P2 | withdrawn | 0 | Sunnybrook Health Sciences Centre | Nov 2019 |
| NCT03175549 | Medication Development in Alcoholism: Apremilast Versus Placebo | P2 | completed | 51 | The Scripps Research Institute | Nov 2017 | |
| NCT03576287 | Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis | P1/P2 | unknown | 15 | Tanja Todberg, MD | Jul 2017 | |
| NCT03036995 | Rapid Vitiligo | Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO | P2 | completed | 80 | Centre Hospitalier Universitaire de Nice | Mar 2017 |
| NCT03399708 | IMAPA | Immune Metabolic Associations in Psoriatic Arthritis | — | completed | 60 | NHS Greater Glasgow and Clyde | Jun 2017 |
| NCT03239106 | A Study Examining the Medication Apremilast as Treatment for Chronic Itch | P2 | completed | 10 | Washington University School of Medicine | Dec 2017 | |
| NCT04572997 | APLANTUS | Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS) | P2 | completed | 21 | Kristian Reich | Nov 2018 |
| NCT03123016 | Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo | P2 | completed | 23 | Icahn School of Medicine at Mount Sinai | Apr 2017 | |
| NCT03741933 | CHD | Apremilast and Moderate to Severe Chronic Hand Dermatitis | P4 | withdrawn | 0 | George Washington University | Feb 2019 |
| NCT02576678 | CC-10004 | A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis | P2 | completed | 42 | Amgen | Oct 2015 |
| NCT03191539 | APREMILAST | Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis | P3 | unknown | 56 | Hospital Universitari Vall d'Hebron Research Institute | Nov 2017 |
| NCT02289417 | UC | Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis | P2 | completed | 170 | Amgen | Jan 2015 |
| NCT03146247 | Itch | Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients | P4 | withdrawn | 0 | Diamant Thaci | Oct 2017 |
| NCT03422640 | Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia | P4 | unknown | 20 | Bellevue Dermatology | Jul 2018 | |
| NCT03123471 | STYLE | A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp | P3 | completed | 303 | Amgen | May 2017 |
| NCT03096990 | APOLO | A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium | — | completed | 106 | Amgen | Apr 2017 |
| NCT03097003 | OTELO | A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium | — | completed | 124 | Amgen | Apr 2017 |
| NCT01583374 | POSTURE | Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis | P3 | completed | 490 | Amgen | May 2012 |
| NCT03049267 | SMASH | Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis | P2 | completed | 20 | M.B.A. van Doorn | Feb 2017 |
| NCT03000309 | Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy | P4 | completed | 20 | Derm Research, PLLC | Dec 2016 | |
| NCT02963779 | A Study of LY2775240 in Healthy Participants | P1 | completed | 35 | Eli Lilly and Company | Dec 2016 | |
| NCT02684123 | Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata | N/A | completed | 30 | Icahn School of Medicine at Mount Sinai | Feb 2016 | |
| NCT02695212 | HS | Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa | P2 | completed | 20 | Florida Academic Dermatology Centers | Jul 2016 |
| NCT01307423 | PALACE4 | Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA) | P3 | completed | 529 | Amgen | Dec 2010 |
| NCT01212770 | PALACE 3 | PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis | P3 | completed | 505 | Amgen | Sep 2010 |
| NCT01212757 | PALACE2 | PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis | P3 | completed | 488 | Amgen | Sep 2010 |
| NCT02400749 | Apremilast in Palmo-Plantar Psoriasis | P4 | completed | 100 | Innovaderm Research Inc. | May 2015 | |
| NCT01232283 | ESTEEM 2 | Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis. | P3 | completed | 413 | Amgen | Nov 2010 |
| NCT02777554 | A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults | P1 | completed | 144 | Amgen | Aug 2016 | |
| NCT02425826 | UNVEIL | A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis. | P4 | completed | 221 | Amgen | Apr 2015 |
| NCT01194219 | ESTEEM 1 | Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis | P3 | completed | 844 | Amgen | Sep 2010 |
| NCT01925768 | Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis | P3 | completed | 219 | Amgen | Sep 2013 | |
| NCT02558361 | Treatment With Apremilast in Patients With Psoriatic Arthritis | P4 | withdrawn | 0 | University of South Florida | Apr 2016 | |
| NCT01172938 | PALACE-1 | Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis | P3 | completed | 504 | Amgen | Jun 2010 |
| NCT02802735 | Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean Subjects | P1 | completed | 28 | Amgen | Jun 2016 | |
| NCT02412644 | Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis | P4 | completed | 29 | Psoriasis Treatment Center of Central New Jersey | May 2015 | |
| NCT01690299 | Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis | P3 | completed | 250 | Amgen | Oct 2012 | |
| NCT02087943 | Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis | P2 | completed | 191 | Amgen | Jun 2014 | |
| NCT02641353 | PK | Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension | P1 | completed | 34 | Amgen | Jan 2016 |
| NCT01988103 | CC-10004 | Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis | P2 | completed | 254 | Amgen | Jul 2013 |
| NCT00773734 | CC-10004 | Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study) | P2 | completed | 352 | Amgen | Sep 2008 |
| NCT02236988 | Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men | P1 | completed | 80 | Amgen | Jan 2014 | |
| NCT01250548 | CARAT | The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT) | P2 | completed | 34 | Baylor Research Institute | May 2010 |
| NCT01045551 | Open Label Pilot Study of Apremilast in Treatment of Rosacea | P2 | completed | 10 | Julian M. Mackay-Wiggan | Jun 2010 | |
| NCT01200472 | CC-10004 | Efficacy Study of Apremilast (CC-10004) in Subjects With Erosive Hand Osteoarthritis | P2 | completed | 30 | University of Erlangen-Nürnberg Medical School | Aug 2010 |
| NCT01200264 | CPP | Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy | P2 | withdrawn | 0 | Duke University | Sep 2010 |
| NCT01285310 | Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis | P2 | terminated | 237 | Amgen | Dec 2010 | |
| NCT00866359 | CC-10004 | A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease | P2 | completed | 111 | Amgen | Aug 2009 |
| NCT01634191 | Effects of Age and Sex on the Pharmacokinetics of Apremilast in Healthy Adults | P1 | completed | 36 | Amgen | Feb 2012 | |
| NCT01561963 | A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast | P1 | completed | 21 | Amgen | Feb 2012 | |
| NCT01634178 | CC-10004 | Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Adults | P1 | completed | 46 | Amgen | Feb 2012 |
| NCT01041625 | CC-10004 | Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus | P2 | unknown | 10 | Virginia Clinical Research, Inc. | Feb 2010 |
| NCT01204138 | CATARA | Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA | P2 | withdrawn | 0 | Stanford University | Sep 2010 |
| NCT01140503 | A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis | N/A | terminated | 5 | Stanford University | Feb 2010 | |
| NCT01393158 | Apremilast for Atopic Dermatitis - A Pilot Study in Adults | P2 | completed | 16 | Oregon Health and Science University | May 2009 | |
| NCT00889421 | Apremilast in the Treatment of Uveitis | P1/P2 | terminated | 3 | Oregon Health and Science University | Nov 2009 | |
| NCT00944658 | START | Spondylitis Trial of Apremilast for Better Rheumatic Therapy | P2 | completed | 38 | Imperial College London | Aug 2009 |
| NCT00997581 | Apremilast Therapy for Acute Gouty Arthritis | P2 | withdrawn | 0 | Dartmouth-Hitchcock Medical Center | Apr 2010 | |
| NCT01074502 | Apremilast in the Treatment of Moderate to Severe Acne | P2 | terminated | 3 | University of North Carolina, Chapel Hill | Feb 2010 | |
| NCT00931242 | Study of Apremilast in Atopic or Contact Dermatitis | P2 | completed | 10 | Tufts Medical Center | Jun 2009 | |
| NCT00456092 | CC-10004 | Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis | P2 | completed | 204 | Amgen | Mar 2007 |
| NCT00521339 | Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis | P2 | completed | 31 | Amgen | Aug 2007 |
Apremilast clinical trials: frequently asked questions
- How many Apremilast clinical trials are there?
- 137 Apremilast clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 13 are actively recruiting participants. 91 are marked completed.
- Are Apremilast clinical trials recruiting in 2026?
- Yes — 13 Apremilast trials are actively recruiting in 2026, with 13 U.S. sites across 13 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Apremilast being studied for?
- Apremilast is being studied for Psoriasis, Psoriatic Arthritis, Plaque Psoriasis, Arthritis, Psoriatic, Alcohol Use Disorder and 78 more. The trials are grouped by indication on this page.
- What phase is Apremilast in?
- Apremilast clinical trials span 29 Phase 4, 37 Phase 3, 40 Phase 2, 10 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Apremilast clinical trials?
- The lead sponsor across the most Apremilast trials is Amgen, with 70 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Apremilastas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: